<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230420057970N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-11-04</date_registration>
      <primary_sponsor>Combined Militray Hospital</primary_sponsor>
      <public_title>3D plates in mandible fractures</public_title>
      <acronym>RCT</acronym>
      <scientific_title>Comparison between 3-D Plates and Conventional miniplates in the management of parasymphysis and symphysis fractures of the mandible.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-17</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>62</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/78522</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly assigned into two groups using sealed envelope method. Individuals with odd numbers in the envelopes will be included in Group A and even numbers in Group B. A third person not being part of the study will open the envelopes and the patients will be allocated to the mentioned groups, Blinding description: Patients were blinded as they were not informed about the treatment modality used for management of their ailment, but consent was taken. An independent assessor, who will be a senior and experienced Oral and Maxillofacial Surgeon and will not be part of the study, will assess patients, he will also be blinded.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Fracture of mandible..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  Group A: Mandible fractures will be fixated with 3D plates according to Champys lines of Osteosynthesis. All cases will be treated under strict aseptic conditions, general anesthesia and local anesthesia ( 1.8ml 2% Lignocaine with Adrenaline 1:100,000;Septodont, USA) given in fracture vicinity by a single surgical team. Temporary MMF will be done using eyelets and tie wires (prestretched, round, stainless steel, 24 gauge, 6 inches in length) to achieve best possible occlusion. One titanium 3-D plates, square shaped 4 hole, 2mm thick [Grade 4] (Moin International CE, Pakistan) will be adapted and secured with the help of titanium monocortical screws [Grade 5] around the fracture line in the subapical region. 7mm length screws will be inserted in upper holes and 9mm in lower hole. Muscle and then mucosal closure will be done with vicryl 3.0 (Ethicon, USA) respectively. All patients will be prescribed I/V pre-op broad spectrum antibiotics (Inj I/V Augmentine 1.2g BD, Inj I/V Flagyl 500mg BD) which will be continued post-op along with analgesics (Inj I/V Toradol 30mg TDS), antiemetic (Inj I/V Maxalon 10mg STAT) and fluids (Inf I/V Ringer Lactate + 5% Dextrose over 24 hrs) for 3 days according to the ward protocol. Post-op MMF will only be done if occlusion is not statsfactory. Patient will be advised liquid diet and strict oral hygiene instructions (intraoral irrigation and suctioning, 24 hours after the procedure with Enziclor (0.15% Benzydamine Hydrochorlide/ 0.2% Chlorhexidine Gluconate)( Platinum Pharmacueticals Pvt Ltd, Pakistan) 3 times a day, after meals. Intervention 2: Control group: Group B: Mandible fractures will be Fixated with conventional mini plates According to Champys line of Osteosynthesis. All cases will be treated under strict aseptic conditions, general anesthesia and local anesthesia (1.8ml 2% Lignocaine with Adrenaline 1:100,000;Septodont, USA) given in fracture vicinity by a single surgical team. Temporary MMF will be done using eyelets and tie wires (prestretched, round, stainless steel, 24 gauge, 6 inches in length) to achieve best possible occlusion. Conventional titanium miniplates (Moin International CE, Pakistan); one 4/5 hole[Grade 5] in subapical region with 7mm [Grade 4] screws and 5/6 hole [Grade 5] in inferior boarder region with 9mm screws [Grade4] will be adapted and secured. Number of hole can Increase as per obliqueness of fracture line. Muscle and then mucosal closure will be done with vicryl 3.0 (Ethicon, USA) respectively. All patients will be prescribed I/V pre-op broad spectrum antibiotics (Inj I/V Augmentine 1.2g BD, Inj I/V Flagyl 500mg BD) which will be continued post-op along with analgesics (Inj I/V Toradol 30mg TDS), antiemetic (Inj I/V Maxalon 10mg STAT)  and fluids for 3 days (Inf I/V Ringer Lactate + 5% Dextrose over 24 hrs) according to the ward protocol. Post-op MMF will only be done if per-op stability of the fractured segments is not achieved. Patient will be advised liquid diet and strict oral hygiene instructions (intraoral irrigation and suctioning, 24 hours after the procedure with Enziclor (0.15% Benzydamine Hydrochorlide/ 0.2% Chlorhexidine Gluconate)( Platinum Pharmacueticals Pvt Ltd, Pakistan) 3 times a day after meals.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Lt. Col Muhammad Chaudry Usman</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>2G3R+9W5, Mall Rd, Peshawar Cantonment</address>
        <city>Peshawar</city>
        <country1>Pakistan</country1>
        <zip>25000</zip>
        <telephone>+92 348 3488043</telephone>
        <email>usman.chy@gmail.com</email>
        <affiliation>Combined Military Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Aminah Khan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>House#494, Main Road, Gulber# 2</address>
        <city>Peshawar</city>
        <country1>Pakistan</country1>
        <zip>25000</zip>
        <telephone>+92 333 6545366</telephone>
        <email>aminahkhan93@gmail.com</email>
        <affiliation>Combined Military Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Pakistan</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pain following history of fall/ RTA/ trauma
Age 18-50 years
American Society of Anesthesiologist ASA Class 1
Isolated mandible fractures</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Infection at site of fracture
Comminuted fractures
Panfacial trauma
Patients with a bone pathology (osteomyelitis, osteoporosis and paget’s Disease)
Chronic Illness (uncontrolled diabetes, asthma and hypertension)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S02.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of mandible</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Group A: Mandible fractures will be fixated with 3D plates according to Champys lines of Osteosynthesis. All cases will be treated under strict aseptic conditions, general anesthesia and local anesthesia ( 1.8ml 2% Lignocaine with Adrenaline 1:100,000;Septodont, USA) given in fracture vicinity by a single surgical team. Temporary MMF will be done using eyelets and tie wires (prestretched, round, stainless steel, 24 gauge, 6 inches in length) to achieve best possible occlusion. One titanium 3-D plates, square shaped 4 hole, 2mm thick [Grade 4] (Moin International CE, Pakistan) will be adapted and secured with the help of titanium monocortical screws [Grade 5] around the fracture line in the subapical region. 7mm length screws will be inserted in upper holes and 9mm in lower hole. Muscle and then mucosal closure will be done with vicryl 3.0 (Ethicon, USA) respectively. All patients will be prescribed I/V pre-op broad spectrum antibiotics (Inj I/V Augmentine 1.2g BD, Inj I/V Flagyl 500mg BD) which will be continued post-op along with analgesics (Inj I/V Toradol 30mg TDS), antiemetic (Inj I/V Maxalon 10mg STAT) and fluids (Inf I/V Ringer Lactate + 5% Dextrose over 24 hrs) for 3 days according to the ward protocol. Post-op MMF will only be done if occlusion is not statsfactory. Patient will be advised liquid diet and strict oral hygiene instructions (intraoral irrigation and suctioning, 24 hours after the procedure with Enziclor (0.15% Benzydamine Hydrochorlide/ 0.2% Chlorhexidine Gluconate)( Platinum Pharmacueticals Pvt Ltd, Pakistan) 3 times a day, after meals.</i_keyword>
      <i_keyword>Control group: Group B: Mandible fractures will be Fixated with conventional mini plates According to Champys line of Osteosynthesis. All cases will be treated under strict aseptic conditions, general anesthesia and local anesthesia (1.8ml 2% Lignocaine with Adrenaline 1:100,000;Septodont, USA) given in fracture vicinity by a single surgical team. Temporary MMF will be done using eyelets and tie wires (prestretched, round, stainless steel, 24 gauge, 6 inches in length) to achieve best possible occlusion. Conventional titanium miniplates (Moin International CE, Pakistan); one 4/5 hole[Grade 5] in subapical region with 7mm [Grade 4] screws and 5/6 hole [Grade 5] in inferior boarder region with 9mm screws [Grade4] will be adapted and secured. Number of hole can Increase as per obliqueness of fracture line. Muscle and then mucosal closure will be done with vicryl 3.0 (Ethicon, USA) respectively. All patients will be prescribed I/V pre-op broad spectrum antibiotics (Inj I/V Augmentine 1.2g BD, Inj I/V Flagyl 500mg BD) which will be continued post-op along with analgesics (Inj I/V Toradol 30mg TDS), antiemetic (Inj I/V Maxalon 10mg STAT)  and fluids for 3 days (Inf I/V Ringer Lactate + 5% Dextrose over 24 hrs) according to the ward protocol. Post-op MMF will only be done if per-op stability of the fractured segments is not achieved. Patient will be advised liquid diet and strict oral hygiene instructions (intraoral irrigation and suctioning, 24 hours after the procedure with Enziclor (0.15% Benzydamine Hydrochorlide/ 0.2% Chlorhexidine Gluconate)( Platinum Pharmacueticals Pvt Ltd, Pakistan) 3 times a day after meals.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Stability will be checked between both the plating systems. Timepoint: Just after plate Insertion, 1 week, 4 weeks. Method of measurement: Checked clinically by manual manipulation to assess mobility of fractured segments post-op after fixation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Malocclusion. Timepoint: 1st post op day, 1week, 4 week. Method of measurement: Deflection from the normal relation or alignment of the teeth to other teeth in the same arch and/or to the teeth in the opposing arch, 2mm or more space between maxillary and mandibular teeth.</sec_outcome>
      <sec_outcome>Post op pain. Timepoint: 1st post op day, 1 week, 4 week. Method of measurement: Evaluated by Visual analog scale.</sec_outcome>
      <sec_outcome>Wound Dehisence. Timepoint: 1st post op day, 1 week, 4 week. Method of measurement: Plate exposure and visibility in the oral cavity.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Combined Militray Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-29</approval_date>
        <contact_name>Ethical Review Committee for Dental Research, 30 MDC</contact_name>
        <contact_address>2G3R+9W5, Mall Rd, 30 MDC, Peshawar Cantonment Peshawar Khyber Pakhtun Khawa Pakistan</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
